ArticleAlzheimer's & dementia (New York, N. Y.)
Vascular cognitive impairment and dementia drug-development pipeline 2025.
Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThere are currently no approved medicines for vascular cognitive impairment and dementia (VCID).
methodsWe reviewed clinical trials across nine registries and included, summarized, and evaluated trials that had not yet published peer-reviewed results by August 22, 2025.
resultsWe found 88 clinical trials using 62 drugs. Cardiovascular disease-targeted therapies accounted for 37% (23 drugs). Synthetic and plant-based cognitive function enhancers accounted for 21% (13 drugs) each. Drugs targeting neuropsychiatric symptoms comprised 10% of the pipeline (six agents), biological disease-targeted therapies 5% (three agents), and other drugs 6% (four agents). There were 30 trials assessing 25 drugs in Phase 4, 24 trials assessing 21 drugs in Phase 3, 29 trials assessing 28 drugs in Phase 2, and five trials assessing four drugs in Phase 1. DISCUSSION: While small relative to Alzheimer's disease (138 drugs, 182 trials in 2025), the drug pipeline for VCID shows some promise and will require further investment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.